Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Liabilities and Shareholders Equity: 2021-2025

Historic Liabilities and Shareholders Equity for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Sep 2025 value amounting to $712.3 million.

  • Kiniksa Pharmaceuticals International's Liabilities and Shareholders Equity rose 28.28% to $712.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.6 billion, marking a year-over-year increase of 19.11%. This contributed to the annual value of $580.6 million for FY2024, which is 10.30% up from last year.
  • Per Kiniksa Pharmaceuticals International's latest filing, its Liabilities and Shareholders Equity stood at $712.3 million for Q3 2025, which was up 7.74% from $661.1 million recorded in Q2 2025.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's Liabilities and Shareholders Equity peaked at $712.3 million during Q3 2025, and registered a low of $210.6 million during Q2 2022.
  • Its 3-year average for Liabilities and Shareholders Equity is $555.2 million, with a median of $542.4 million in 2024.
  • In the last 5 years, Kiniksa Pharmaceuticals International's Liabilities and Shareholders Equity fell by 25.77% in 2022 and then skyrocketed by 130.00% in 2023.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's Liabilities and Shareholders Equity (Quarterly) stood at $232.8 million in 2021, then surged by 97.45% to $459.7 million in 2022, then climbed by 14.50% to $526.3 million in 2023, then climbed by 10.30% to $580.6 million in 2024, then rose by 28.28% to $712.3 million in 2025.
  • Its last three reported values are $712.3 million in Q3 2025, $661.1 million for Q2 2025, and $599.3 million during Q1 2025.